Davide F.
- Country
- Italy
- Department
- ONCOLOGIA
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Evaluation of Low-Intensity Therapy with Gilteritinib, Venetoclax, and Glasdegib Versus High-Intensity Therapy in Relapsed/Refractory Acute Myeloid Leukemia
- Phase II Study of Asciminib Hydrochloride Monotherapy or Combined with Nilotinib in First-Line Treatment of BCR-ABL1+ Chronic Myeloid Leukemia
Data & Insights
Has run more than one trial at 33 of 132 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating BCR-ABL1-positive Chronic Myeloid Leukemia (CML), focusing on innovative therapeutic approaches for patients in the early chronic phase of the disease.
- Targeted Leukemia Therapy
- Molecular Response Assessment
- First-line Treatment Strategies
The investigator's work centers on evaluating novel treatment combinations and single-agent therapies for optimizing patient outcomes in CML management.
Molecular Therapeutics
The investigator explores targeted molecular treatments in hematologic malignancies, with particular attention to tyrosine kinase inhibition strategies.
- Targeted Drug Development
- Combination Therapy Approaches
- Treatment Response Monitoring
Their research interests include investigating therapeutic agents that target specific molecular pathways in leukemia treatment.
Disease Monitoring
The investigator focuses on deep molecular response assessment in leukemia treatment, emphasizing the importance of precise monitoring in clinical care.
- Response Evaluation Methods
- Treatment Efficacy Assessment
- Clinical Outcomes Analysis
Their work involves evaluating treatment effectiveness through sophisticated molecular monitoring techniques.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.